OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) ? Opportunity Analysis and Forecasts to 2017 - Event-Driven Update
Reportstack, provider of premium market research reports announces the addition of OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) ? Opportunity Analysis and Forecasts to 2017 - Event-Driven Update market report to its offering
The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.
View full press release